Études psychédéliques Vincent Verroust, doctorant à l'EHESS ( CAK )Cet enseignant est référent pour cette UE https://enseignements-2019.ehess.fr/2019/ue/2998/ Mardi de 18 h à 19 h 30 (amphithéâtre Rouelle, Muséum national d'Histoire naturelle, 57 rue Cuvier 75005 Paris), les 26 novembre, 17 décembre 2019, 28 janvier, 25 février, 31 mars, 28 avril, 26 mai et 30 juin 2020 Plan pour trouver l'amphi : https://drive.google.com/file/d/1h-oVy6oTh7UTMh84X-o448VhCCmBMp-M/view?usp=sharing NB : merci d'arriver en avance pour éviter de trouver portes closes. Le terme psychedelic a été forgé en 1956 par le psychiatre britannique Humphry Osmond (1917 - 2004) pour qualifier les effets psychiques de la mescaline et du LSD, deux substances psychotropes sur lesquelles [...]
Lire la suitePatient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]
Lire la suiteLong-term use of psychedelic drugs is associated with differences in brain structure and personality in humans José Carlos Bouso, FernandaPalhano-Fontes, Antoni Rodríguez-Fornells, Sidarta Ribeiro, Rafael Sanches, José Alexandre S. Crippa, Jaime E.C. Hallak, Draulio B. de Araujo, Jordi Riba European Neuropsychopharmacology, 2015, 25, 483–492 http://dx.doi.org/10.1016/j.euroneuro.2015.01.008 Abstract Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception,emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that psychedelic 5-hydroxytryptamine (5HT)2A [...]
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : Pharmacologie, Neurophysiologie, Psychologie, Dr Christian SUEUR, GRECC, décembre 2019 Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, Culture, Spiritualité, Chamanisme Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca….
Lire la suiteLSD enhances suggestibility in healthy volunteers R. L. Carhart-Harris, M. Kaelen, M. G. Whalley, M. Bolstridge, A. Feilding, D. J. Nutt Psychopharmacology, 2014 DOI 10.1007/s00213-014-3714-z Abstract Rationale : Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control. Objectives : The present study sought to test the effect of LSD on suggestibility in a modern research study. Methods : Ten healthy volunteers were administered with intravenous (i.v.) LSD (40–80 μg) in a within-subject placebocontrolled design. Suggestibility and cued mental imagery were assessed using the Creative [...]
Lire la suiteThe psychedelic renaissance : the next trip for psychiatry ? J. R. Kelly, A. Baker, M. Babiker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2019, 1 - 5 doi : 10.1017/ipm.2019.39 Abstract The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological processes involve alterations in brain connectivity, together with altered amygdala and default mode network activity. At the cellular level, psychedelics promote [...]
Lire la suiteSerotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer Rafael Guimarães dos Santos, José Carlos Bouso and Jaime E. C. Hallak BMC Psychiatry, 2019, 19, 321 https://doi.org/10.1186/s12888-019-2288-z Abstract In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not included. In [...]
Lire la suiteAntidepressive and anxiolytic effects of ayahuasca : a systematic literature review of animal and human studies Rafael G. dos Santos, Flavia L. Osorio, José Alexandre S. Crippa, Jaime E.C. Hallak Revista Brasileira de Psiquiatria, 2016, 38, 65–72 doi:10.1590/1516-4446-2015-1701 ABSTRACT Objective : To conduct a systematic literature review of animal and human studies reporting anxiolytic or antidepressive effects of ayahuasca or some of its isolated alkaloids (dimethyltryptamine, harmine, tetrahydroharmine, and harmaline). Methods : Papers published until 3 April 2015 were retrieved from the PubMed, LILACS and SciELO databases following a comprehensive search strategy and using a predetermined set of criteria for article selection. Results : Five hundred and [...]
Lire la suiteThe Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Draulio B. Araujo Frontiers in Pharmacology, 2019, Volume 10, Article 1325, 1-10. doi : 10.3389/fphar.2019.01325 Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in [...]
Lire la suitePsilocybin-assisted therapy for depression : How do we advance the field ? Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams, David J Castle Australian & New Zealand Journal of Psychiatry, 2019, 1–7 Doi : 10.1177/0004867419888575 Abstract In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use [...]
Lire la suite